Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$83.90
-3.5%		$73.74
$54.11
▼
$87.85
$31.66B1.415.27 million shs1.47 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$32.03
-0.4%		$31.54
$13.74
▼
$65.30
$7.41B2.427.11 million shs2.27 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-0.42%+16.15%+22.02%+44.04%+14.02%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+3.99%+9.11%-12.71%+18.96%-49.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$83.90
-3.5%		$73.74
$54.11
▼
$87.85
$31.66B1.415.27 million shs1.47 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$32.03
-0.4%		$31.54
$13.74
▼
$65.30
$7.41B2.427.11 million shs2.27 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-0.42%+16.15%+22.02%+44.04%+14.02%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+3.99%+9.11%-12.71%+18.96%-49.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.89
Moderate Buy$88.715.73% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.19
Hold$31.43-1.86% Downside

Current Analyst Ratings Breakdown

Latest DXCM and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2026
DexCom, Inc. stock logo
DXCM
DexCom
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$86.00 ➝ $96.00
8/3/2026
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$82.00 ➝ $90.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$94.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$88.00 ➝ $95.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$105.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$84.00 ➝ $88.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$80.00 ➝ $90.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$87.00 ➝ $93.00
7/31/2026
DexCom, Inc. stock logo
DXCM
DexCom
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$90.00 ➝ $95.00
7/24/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$23.00 ➝ $27.00
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.79$2.66 per share31.53$6.95 per share12.07
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B3.16$0.87 per share36.83$2.38 per share13.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5333.1627.241.4820.12%35.94%14.75%N/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.09N/A61.6086.74-0.56%6.10%1.52%8/10/2026 (Estimated)

Latest DXCM and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$0.0490N/AN/AN/A$698.90 millionN/A
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
5/11/2026Q1 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.18
1.69
1.56

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442231.46 million204.24 millionOptionable

Recent News About These Companies

Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)
 |  newsfilecorp.comN
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)
 |  newsfilecorp.comN
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339370/3448/en/hims-hers-health-inc-hims-shareholders-who-lost-money-contact-law-offices-of-howard-g-smith-about-continuing-securities-fraud-investigation.html
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
August 4 at 7:02 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338972/0/en/nyse-hims-investigation-kessler-topaz-meltzer-check-llp-encourages-hims-hers-health-inc-nyse-hims-investors-to-contact-the-firm.html
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 4 at 3:12 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338747/0/en/securities-fraud-investigation-into-hims-hers-health-inc-hims-continues-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r-cruz.html
Why Hims & Hers Is the Perfect Acquisition Target (Even If a Deal Never Happens)
August 4 at 10:15 AM  |  247wallst.comhttps://247wallst.com/investing/2026/08/04/why-hims-hers-is-the-perfect-acquisition-target-even-if-a-deal-never-happens/?utm_source=snapi
First Trust Advisors LP Sells 87,063 Shares of Hims & Hers Health, Inc. $HIMS
August 4 at 3:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-trust-advisors-lp-sells-87063-shares-of-hims-hers-health-inc-hims-2026-08-04/
Kaplan Fox Announces a Securities Investigation into Hims & Hers Health, Inc. (HIMS) - Investors Encouraged to Contact the Firm
August 3 at 8:00 PM  |  newsfilecorp.comN
Market Matters Ep. 12: How HIMS Could Benefit From FDA Changes
August 3 at 3:00 PM  |  youtube.comY
NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
August 3 at 2:07 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260803743478/en/nyse-hims-investigation-alert-kessler-topaz-meltzer-check-llp-encourages-hims-hers-health-inc.-nyse-hims-investors-to-contact-the-firm/
Hims & Hers Health (NYSE:HIMS) Trading Up 8.4% - What's Next?
August 3 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hims-hers-health-nysehims-trading-up-84-whats-next-2026-08-03/
Bear statue on a trading desk surrounded by red downward stock charts on multiple monitors in a trading floor.
Bearish Pressure Is Building Around These 3 Stocks
...
August 3 at 11:30 AM  |  marketbeat.comhttps://www.marketbeat.com/articles/bearish-pressure-is-building-around-these-3-stocks/
Hims & Hers Health (HIMS) Projected to Release Quarterly Earnings on Monday
August 3 at 9:25 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hims-hers-health-hims-projected-to-release-quarterly-earnings-on-monday-2026-08-03/
FTC Sues Hims & Hers Over Health Privacy And Billing Practices
August 1, 2026  |  usnews.comhttps://www.usnews.com/news/health-news/articles/2026-07-31/ftc-sues-hims-hers-over-health-privacy-and-billing-practices
FTC sues Hims and Hers over sharing private health data
August 1, 2026  |  newsbytesapp.comN
Hims and Hers accused of sharing GLP-1 patients' health data with Meta
August 1, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/hims-and-hers-accused-of-sharing-glp-1-patients-health-data-with-meta/ar-AA29a0mm
“Hims & Hers”… And Allegedly Everyone Else: FTC Says Your Health Data Got Shared
August 1, 2026  |  yahoo.comhttps://www.yahoo.com/news/politics/articles/hims-hers-allegedly-everyone-else-120005566.html
Avidity Partners Management LP Invests $1.56 Million in Hims & Hers Health, Inc. $HIMS
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-avidity-partners-management-lp-invests-156-million-in-hims-hers-health-inc-hims-2026-08-01/
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law
July 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hims-investors-have-opportunity-to-join-hims--hers-health-inc-fraud-investigation-with-sbs-law-302839679.html
Health Brief: FTC showdown with Hims & Hers
July 31, 2026  |  washingtonpost.comhttps://www.washingtonpost.com/wp-intelligence/health-brief/2026/07/30/health-brief-ftc-showdown-with-hims-hers/
Hims & Hers Health: Still An Undervalued Company With Tremendous Upside
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928371-hims-hers-health-still-undervalued-stock-tremendous-upside

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A semiconductor wafer with the SK hynix logo displayed inside a manufacturing fabrication facility.
SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
By Thomas Hughes | July 7, 2026
Rocket Lab Electron rocket on coastal launch pad with company logo overlay, symbolizing space tech integration strategy.
Rocket Lab’s Stock Drop Comes With a Bullish Twist
By Ryan Hasson | July 10, 2026
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Hims and Hers Health logo displayed alongside branded personal care product bottles on bathroom countertops.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
By Jessica Mitacek | July 6, 2026
Bear statue on a trading desk surrounded by red downward stock charts on multiple monitors in a trading floor.
Bearish Pressure Is Building Around These 3 Stocks
By Jessica Mitacek | August 3, 2026
DexCom stock logo

DexCom NASDAQ:DXCM

$83.90 -3.04 (-3.50%)
As of 10:28 AM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$32.03 -0.13 (-0.40%)
As of 10:28 AM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas